These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8104829)

  • 1. Prognostic significance of plasma prolactin in breast cancer: comparison with the expression of c erb B-2 oncoprotein.
    Bhatavdekar JM; Patel DD; Sherbet GV; Giri DD; Karelia NH; Vora HH; Shah NG; Suthar TP; Nadkarni SP; Balar DB
    Eur J Surg Oncol; 1993 Oct; 19(5):409-13. PubMed ID: 8104829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance.
    Tervahauta A; Eskelinen M; Syrjänen S; Lipponen P; Pajarinen P; Syrjänen K
    Anticancer Res; 1991; 11(5):1677-81. PubMed ID: 1685075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
    Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
    J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease.
    Cameron B; Gown AM; Tamimi HK
    Am J Obstet Gynecol; 1994 Jun; 170(6):1616-21; discussion 1621-2. PubMed ID: 7911272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissues in invasive and non-invasive human breast lesions.
    Pechoux C; Chardonnet Y; Noël P
    Anticancer Res; 1994; 14(3B):1343-60. PubMed ID: 7915095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.
    Scorilas A; Yotis J; Gouriotis D; Keramopoulos A; Ampela K; Trangas T; Talieri M
    Anticancer Res; 1993; 13(5C):1895-900. PubMed ID: 7903524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
    Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
    Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
    Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
    Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
    Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
    Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.
    Heintz NH; Leslie KO; Rogers LA; Howard PL
    Arch Pathol Lab Med; 1990 Feb; 114(2):160-3. PubMed ID: 1967929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
    Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
    Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
    Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
    Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
    Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
    Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis.
    Fontana X; Ferrari P; Namer M; Peysson R; Salanon C; Bussiere F
    Anticancer Res; 1994; 14(5B):2099-104. PubMed ID: 7840506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.